Suppr超能文献

健高素与赛增的生物等效性。

Bioequivalence of Genotropin and Somatonorm.

作者信息

Wilton P, Widlund L, Guilbaud O

机构信息

Medical Department, Kabi Vitrum Peptide Hormones AB, Stockholm, Sweden.

出版信息

Acta Paediatr Scand Suppl. 1987;337:118-21. doi: 10.1111/j.1651-2227.1987.tb17141.x.

Abstract

The bioequivalence parameters, AUC, Cmax and Tmax were calculated from serum hGH concentration-time curves after subcutaneous injections of Genotropin (recombinant somatropin) and Somatonorm (somatrem) in a two-period crossover study in 11 healthy men aged 21-35 years. Cmax was 53.4 and 62.9 mIU/litre and Tmax was 5.3 and 4.0 hours for Genotropin and Somatonorm, respectively. Criteria for bioequivalence were fulfilled for AUC. The bioavailability of Genotropin given subcutaneously was determined from the data obtained in the study above, and after an intravenous injection of Genotropin in the same dose (0.1 IU/kg body weight). The measured bioavailability of 71% could be an overestimate due to interference by endogenous hGH.

摘要

在一项针对11名年龄在21至35岁的健康男性的两阶段交叉研究中,皮下注射健高灵(重组人生长激素)和思增(蛋氨生长抑素)后,根据血清hGH浓度-时间曲线计算生物等效性参数AUC、Cmax和Tmax。健高灵和思增的Cmax分别为53.4和62.9 mIU/升,Tmax分别为5.3和4.0小时。AUC满足生物等效性标准。皮下注射健高灵的生物利用度是根据上述研究以及在同一剂量(0.1 IU/千克体重)静脉注射健高灵后获得的数据确定的。由于内源性hGH的干扰,测得的71%的生物利用度可能被高估。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验